Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 5811-5820 Newer>

The Motley Fool February 15, 2005 Dave Marino-Nachison	Don't Pity Pitney Bowes The company's shares have recovered from legal settlement sticker shock.
The Motley Fool February 15, 2005 Steven Mallas	Playboy's Silky Earnings The company is on a steamy track, but there are still areas begging for attention. Those who own the stock are probably, in an overall sense, satisfied with the results.
The Motley Fool February 15, 2005 Alyce Lomax	The Great Wall of Coinstar Coinstar's mission is not only to turn people's spare change into cash, but also to increase the profitability of those front walls in the stores. But Coinstar gave a rather subdued view of the first quarter, giving investors something to be leery about.
The Motley Fool February 15, 2005 Stephen D. Simpson	The Arch Capital Advantage The offshore insurer opportunistically moves in and out of insurance lines to grow the business. While it is probably true that Arch Capital won't be able to maintain its current level of growth or return on equity, it appears as though current valuations are overdiscounting the coming slowdown.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool February 15, 2005 Tom Taulli	TriZetto Shows Improving Health After much restructuring, the health-care software provider scored a particularly important achievement: a profitable 2004.
The Motley Fool February 15, 2005 Seth Jayson	Tough Love for Circuit City A private buyout offer gives long-suffering Circuit City shareholders a reason to smile.
The Motley Fool February 15, 2005 Stephen D. Simpson	Psychiatric Solutions Healthy Provider of in-patient mental health services continues to grow rapidly, but debt and dilution are reason for pause.
The Motley Fool February 15, 2005 Stephen D. Simpson	Axcan's Got Guts While growth for this Canadian drug company is a bit sluggish, ITAX could be a major winner. Investors looking at Axcan shares should treat this stock like a hybrid biotech stock.
The Motley Fool February 15, 2005 John Bluis	Red Robin's Royal Performance Restaurant chain reports an impressive 2004. But is the stock too rich?
<Older 5811-5820 Newer> Return to current articles.